# US 2012/0251506 A1 · Methods and compositions relating to neuronal cell and tissue differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251506 A1
- Document ID: US20120251506A1
- Status: Published application
- Kind: A1
- Application number: 13/474,786
- Filed: 2012-05-18
- Published: 2012-10-04
- Earliest claimed: 2004-03-19
- Assignees: The General Hospital Corporation d/b/a Massachusetts General Hospital
- Inventors: Jeffrey D. Macklis; Paola Arlotta; Bradley J. Molyneaux
- Web page: https://patentgrep.com/patent/US20120251506A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 5/0619: {Neurons}
- C12N 2501/60: Transcription factors
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules.

## Claims

### Claim 1

A method for differentiating cells to corticospinal motor neurons (CSMN), comprising
modulating the activity of one or more CSMN fate specification or end stage differentiation gene products by contacting a population of stem cells, neural and/or neuronal progenitors or precursors with a molecule that modulates expression of one or more CSMN fate specification or end stage differentiation gene products or that is a ligand, activator or repressor of the one or more CSMN fate specification or end stage differentiation gene products.

### Claim 2

(canceled)

### Claim 3

A method for promoting growth of cortico spinal motor neurons (CSMN) axons or for inhibiting, preventing or reversing degeneration of corticospinal motor neurons (CSMN) axons, or promoting CSMN survival in situ or in culture, comprising
modulating the activity of one or more CSMN axon guidance/process outgrowth promoting gene products or of one or more CSMN survival gene products by contacting a population of CSMN with a molecule that modulates expression of one or more CSMN axon guidance/process outgrowth promoting gene products that contribute to axon growth or of one or more CSMN survival gene products that contribute to CSMN survival.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more gene products is the expression product of one or more of the genes listed in Table 2 or Table 3.

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more gene products is the expression product of one or more of the CSMN fate specification or end stage differentiation genes listed in Table 4.

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more gene products is the expression product of the fez and/or clim1 genes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more gene products is the expression product of the ctip2, encephalopsin, pcp4, mu-crystallin, csmn1, igfb4, crim1 and/or netrin-G1 genes.

### Claim 10 (depends on 3)

The method of claim 3, wherein the one or more gene products is the expression product of one or more of the CSMN axon guidance/process outgrowth promoting genes listed in Table 4.

### Claim 11 (depends on 3)

The method of claim 3, wherein the one or more gene products is the expression product of the netrin-G1 and/or ctip2 genes.

### Claim 12 (depends on 3)

The method of claim 3, wherein the one or more gene products is the expression product of the one or more of the CSMN survival genes listed in Table 4.

### Claim 13 (depends on 3)

The method of claim 3, wherein the one or more gene products is the expression product of the ctip2, igfb4 and/or mu-crystallin genes.

### Claim at position 14

-18. (canceled)

### Claim 19 (depends on 1)

A method of cell transplantation comprising
differentiating or promoting growth of CSMN as claimed in claim 1,
exposing the cell in vitro to cell growth conditions to form an expanded CSMN cell population, and
administering an amount of the expanded CSMN population or progeny cells produced therefrom to a patient.

### Claim at position 16

-46. (canceled)

### Claim 47

A method for identifying corticospinal motor neurons (CSMN) in a biological sample, comprising
obtaining a biological sample comprising cells, and
analyzing the cells of the biological sample for the presence or expression of one or more CSMN-specific gene products or CSMN-excluded gene products,
wherein the presence or expression of the one or more CSMN-specific gene products is indicative of CSMN in the biological sample, or wherein the absence of the one or more CSMN-excluded gene products is indicative of CSMN in the biological sample.

### Claim 48

(canceled)

### Claim 49 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of one or more of the genes listed in Table 2 or Table 3, or one or more of the CSMN-excluded genes listed in Table 4 or 5.

### Claim 50 (depends on 47)

The method of claim 47, wherein the CSMN-excluded genes are lmo4, lix1 and/or tbr1.

### Claim 51 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of the fez and/or clim1 genes.

### Claim 52 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of the ctip2, encephalopsin, pcp4, mu-crystallin, csmn1, igfb4, crim1 and/or netrin-G1 genes.

### Claim 53 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of one or more of the CSMN axon guidance/process outgrowth promoting genes listed in Table 4.

### Claim 54 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of the netrin-G1 and/or ctip2 genes.

### Claim 55 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of the one or more of the CSMN survival genes listed in Table 4.

### Claim 56 (depends on 47)

The method of claim 47, wherein the one or more gene products is the expression product of the ctip2, igfb4 and/or mu-crystallin genes.

### Claim at position 27

-106. (canceled)
